Neuro-Oncology News

The FDA granted fast track and orphan drug designations to Alpheus Medical’s CV-01 delivery of sonodynamic therapy for treatment of recurrent glioblastoma.

CHICAGO — The addition of veliparib to adjuvant temozolomide did not extend OS or PFS among patients with newly diagnosed MGMT hypermethylated glioblastoma, according to results of a randomized phase 2/phase 3 trial presented at ASCO Annual Meeting.

May is Brain Cancer Awareness Month.

ASCO, in collaboration with the Society for Neuro-Oncology and American Society for Radiation Oncology, has issued a guideline that emphasizes the significance of local therapies for patients with symptomatic brain metastases.

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

Younger patients with diffuse midline glioma experienced prolonged clinical improvement after receiving an investigational chimeric antigen receptor T-cell therapy, study results demonstrated.

Natalia S. Rost, MD, MPH, chair of the AAN science committee, led a discussion to highlight select studies being presented at the AAN’s annual meeting April 2-7 in Seattle.

National Cancer Institute announced the launch of a program that offers molecular characterization of childhood cancers.

Increasing diagnoses of paraneoplastic neurologic syndromes in the U.S. correlates to heightened awareness by physicians as well as greater testing availability, according to a population-based epidemiology study published in Neurology: Neuroimmunology & Neuroinflammation.